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This paper will consider the impact on patient safety of procedural 
controls that can be exercised in the randomised controlled trial study 
design, comment on patient safety issues with current methods for 
post-marketing identification of adverse drug events, and consider 
methods which attempt to give better real-time identification of patient 
safety signals for newly released drugs.
Introduction
The list of drugs with regulatory approval subsequently implicated 
in adverse drug events (ADEs) in large numbers of patients continues 
to grow [1-3]. ADEs are now one of the major causes of morbidity in 
developed countries [4-7]. 
Analyses of ADEs often focus on events surrounding the patient, 
the prescribing staff, the pharmacy staff, the administering staff, and 
the choice of drug, and indeed many ADEs are associated with such 
procedural considerations. These considerations often start with the 
assumption that the drug per se has been approved for safe use in the 
marketplace in accordance with the approved directions. However, the 
root cause of a patient’s ADE may lie in the design of the randomised 
controlled trials (RCTs) that supported the approval of that drug for 
marketing. 
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Abstract
Adverse drug events are one of the major causes of morbidity in developed countries, yet the drugs involved in 
these events have been trialled and approved on the basis of randomised controlled trials (RCTs), regarded as the 
study design that will produce the best evidence.
Though the focus on adverse drug events has been primarily on processes and outcomes associated with the 
use of these approved drugs, attention needs to be directed to the way in which the RCT study design is structured. 
The implementation of controls to achieve internal validity in RCTs may be the very controls that reduce external 
validity, and contribute to the levels of adverse drug events associated with the release of a new drug to the wider 
patient population. 
An examination of these controls, and the effects they can have on patient safety, underscore the importance of 
knowing about how the clinical trials of a drug are undertaken, rather than relying only on the recorded outcomes. 
As the majority of new drugs are likely to be prescribed to older patients who have one or more comorbidities 
in addition to that targeted by a new drug, and as the RCTs of those drugs typically under-represent the elderly and 
exclude patients with multiple comorbidities, timely assessment of drug safety signals is essential. 
It is unlikely that regulatory jurisdictions will undertake a reassessment of safety issues for drugs that are already 
approved. Instead, reliance has been placed on adverse drug event reporting systems. Such systems have a very 
low reporting rate, and most adverse drug events remain unreported, to the eventual cost to patients and healthcare 
systems.
This makes it essential for near real-time systems that can pick up safety signals as they occur, so that 
modifications to the product information (or removal of the drug) can be implemented.
The elephant in the room, as far as newly approved drugs and 
patient safety is concerned, could be what has happened in the pre-
approval clinical trial processes, and the extent to which the RCT study 
design can be unintentionally (or intentionally) manipulated in ways 
that avoid finding evidence of patient safety signals.
As Feinstein has argued, RCTs are “designed and analysed according 
to strategic policies about what questions the trial is intended to ask, 
what answers are to be obtained, what is to be done with the data, and 
who is to be convinced by the results [8]”. From the point of view of 
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a manufacturer, an RCT is a tactical exercise to support approval to 
market a new drug.
Impact of evidence-based medicine (EBM) on the status of 
the RCT
The EBM focus on assigning relative values to evidence sources 
has prioritised evidence produced via RCTs as ‘best evidence’. RCTs 
are now the only acceptable source of evidence in applications to 
most drug regulatory authorities for approval to market a new drug. 
For example, in the U.S., where 50% of the world’s new drugs are 
launched [9-10], the Food and Drug Administration (FDA) is required 
by Federal legislation to accept only evidence from RCTs to support 
applications for approval to market a new drug. This prioritisation of 
RCTs has influenced the perception that evidence derived via an RCT 
is ‘above reproach’ in relation to patient safety. 
Controls used in implementations of the RCT study design
Because the RCT study design is an explicitly scientific activity 
which focuses on the effects of a single intervention on modulating a 
single outcome, a range of controls are used to minimise the effects 
of other factors that could affect the outcome to be measured. These 
include controls that can be applied to select the patients who can 
participate in the clinical trial, controls that can be applied to the scope 
of the research questions that are the focus of the trial, and controls that 
can be applied to the statistical analyses used to assess the outcomes. 
Effects on patient safety of comorbidity and co-medication 
exclusion protocols in RCTs
One of the major control issues which can affect post-approval 
patient safety risk is the application in RCTs of exclusion protocols 
relating to permitted comorbidities and co-medications for 
participants. These exclusion protocols can certainly protect clinical 
trial participants from undue risk, but they can also restrict the 
possibility of finding important evidence of potential risk.
When patients with the morbidity targeted by a new drug also 
have comorbidities and/or take co-medications that are specifically 
excluded from the RCTs of that new drug, then the evidence from 
those trials will not give sufficient information on the effects (and 
safety) of use of the new drug by those patients. When the majority 
of patients in a receiving population have excluded comorbidities 
and/or take excluded co-medications, this can translate to substantial 
post-marketing morbidity and mortality. However, drug licensing 
bodies such as the U.S. FDA do not require evidence that a clinical trial 
population is representative of routine clinical practice [11].
Data from a recent Australian arthritis population study analysing 
linked de-identified hospital separations and medications dispensing 
data showed that 68% of patients over 65 years of age who suffered 
from arthritis also suffered from cardiovascular or cerebrovascular 
diseases and/or took medications that were restricted in the RCTs of the 
arthritis drug rofecoxib [12]. Prior to its voluntary safety withdrawal in 
September 2004, it has been estimated that rofecoxib was implicated 
in more than a 1,000 ADEs in Australian patients, of which about 30% 
resulted in deaths [13]. An estimate of the number of excess cases of 
heart attack or sudden cardiac death in U.S. patients taking rofecoxib 
ranged from 88,000 to 139,000, of whom 30%-40% probably died 
[14]. The patients in rofecoxib RCTs were not typical of the patients 
presenting in the everyday clinical setting. 
Effects on patient safety of age-based exclusion protocols in 
RCTs
Application of age-based participant exclusion protocols in RCTs 
is of particular significance for older age groups. Avorn [7] notes that 
persons aged over 65 years form about 14% of the population in most 
industrialised countries, yet they consume nearly one-third of all drugs. 
The likelihood of experiencing an ADE increases as an individual 
patient’s drug regimen becomes more complex, and this complexity 
is much more frequently found in elderly patients, who experience an 
increasing number of comorbid conditions as they age. 
A new drug can be marketed as providing an effective therapy for 
a specific indication experienced by an elderly patient; however, that 
specific indication is frequently experienced by that elderly patient 
in a radically different context from that addressed in the clinical 
trials of the new drug. As Nelson [15], Wagemakers & Wolffers [16] 
and others [5] note, RCTs typically under-represent the elderly, and 
exclude patients with multiple comorbidities, yet these are the patients 
who are more likely to be prescribed drugs, and experience the highest 
rate of adverse events. Furthermore, older age patients are the group 
that is most frequently prescribed new drugs immediately they are 
approved. Solomon and Avorn observe that once a new drug is out in 
the pharmacy, ‘unexpected’ adverse events are common [5]. However 
these ADEs are not really ‘unexpected’; rather, they are the outcome of 
a clinical trial program that did not include the range of patients who 
would be likely to be prescribed the new drug. Use of inappropriate 
medications by elderly patients remains an important patient safety 
and public health concern [17].
Effects on patient safety of non-inclusion of racial/ethnic 
groups in RCTs
Responses to drugs can be altered by a wide variety of individual 
characteristics that affect the pharmacokinetics of an individual drug, or 
class of drugs. Physiological processes such as absorption, metabolism, 
distribution or excretion of an individual drug or class of drugs can vary 
by age, sex, and, as Evelyn et al. note, they can also vary by racial group 
[18]. For example, Caucasians are more likely than Asians to have 
abnormally low levels of the liver metabolising enzyme cytochrome 
p450 2D6; African Americans do not respond well to several classes of 
antihypertensives. Evelyn et al. advise that attention needs to be paid 
to potential racial and ethnic differences when enrolling patients in 
clinical trials, in order to ensure patient safety for individuals in these 
racial and ethnic groups who may be prescribed the trialled drugs in 
the future [18]. 
Mason et al. [19] consider that excluding patients of ethnic minority 
groups from clinical trials is unethical, introduces substantial bias, and 
will mean that clinical trial findings are based on unrepresentative 
populations. They recommend increased awareness and monitoring 
of recruitment and retention of ethnic minority groups in clinical 
trials, and that analysis of data by ethnicity of subjects should be done 
consistently. Hussain-Gambles [20] agrees that ethnic minority groups 
are frequently under-represented in clinical trials and comments that 
this affects the generalisability of clinical trial findings. Both Evelyn et 
al. [18] and Hussain-Gambles recommend that strategies should be 
developed to increase awareness and monitoring of recruitment and 
retention of ethnic minority groups in clinical trials.
Effects on patient safety of pre-randomisation exclusion 
protocols in RCTs
Rothwell draws attention to the use of pre-randomisation run-in 
periods before a substantive RCT commences. These run-in periods 
can be implemented in order to identify and exclude patients who 
show poor compliance, or patients who show signs that the treatment 
to be trialled is ineffective [11]. The selection of participating centres 
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from hospitals or specialist care, as opposed to primary care, is also a 
pre-RCT selection issue, as patients selected from these settings will 
have a different level of the relevant morbidity from those managed in 
primary care, and can also have a different level of disease management 
[11]. 
Effects on patient safety of selectivity of research questions 
in RCTs
When selectivity in establishing participant exclusion protocols 
is added to selectivity in the formulation of research hypotheses, the 
possibility of finding important evidence of potential patient safety 
risk is further reduced. The definition of the research problem, and the 
selection of variables to be evaluated, can both be made from a position 
of pre-specified interest in anticipated results [8]. If the methodology 
used in a clinical trial pays no attention to a particular issue, then this 
can contribute to the absence of safety signals concerning that issue 
[21].
Again, using rofecoxib as an illustration, it is interesting to see that 
cardiovascular (CVD) endpoints were adjudicated in early clinical trials 
that were submitted to the FDA, but adjudication of these endpoints 
in later trials was modified when it appeared that the drug could be 
associated with thrombotic morbidity [22-23]. This modification of 
endpoints was added to an increased focus on controlling participant 
enrolment in RCTs. This combination acted in synergy to reduce the 
possibility of finding adverse evidence concerning rofecoxib and CVD 
risk [22-23].
Psaty and Furberg consider that inattention to cardiovascular 
events in trials of COX-2-selective NSAIDs contributed to minimising 
the possibility of uncovering evidence of cardiovascular harm, and as 
a result, only a small number of adverse cardiovascular events were 
recorded in studies that were not designed to assess cardiovascular 
outcomes [21]. In testimony to a 2005 U.S. Senate Committee on drug 
safety, Psaty argued that “the failure to pose a question often precludes 
the possibility of obtaining an answer” [24].
Effects on patient safety of using composite endpoints in 
RCTs
Designers of RCTs can combine clinical events (sometimes, events 
of very different severity) in their primary outcome measure. This can 
produce a measure of the overall effect of the treatment (and affords 
greater statistical power), but is problematic when used to guide 
treatment [11]. Kotaska notes that it is “easier to show a statistical 
difference in a combined end point rather than a single end point. Yet 
combined end points can be misleading” [25].
For example, in reviewing the 2002 Heart Protection Study 
involving the drug simvastatin, Conradi and Taylor note that the 
composite endpoint was the “first major vascular event”, which 
included a range of fatal and non-fatal cardiac events or strokes, as 
well as amputations (precipitated by vascular occlusion), or admission 
to hospital for unstable angina [26]. They consider that “this arbitrary 
account of events and procedures does not apply to the risks of an 
individual patient, and cannot be used to explain the potential benefit 
of a proposed treatment” [26]. 
Another illustration is provided in the VIGOR trial data. The 
numbers of patients in the naproxen and rofecoxib arms were equivalent 
in terms of patient years at risk. The number of patients experiencing 
any thrombotic cardiovascular composite endpoint (cardiovascular 
death, myocardial infarction [MI] or cerebrovascular accident) in 
the naproxen arm was 18, and in the rofecoxib arm that figure was 
35. However, whilst only 4 of those 18 adverse cardiovascular events 
in the naproxen arm were MIs, 20 of the 35 adverse cardiovascular 
events in the rofecoxib arm were MIs [27]. However, the published 
report of the VIGOR RCT recorded that the overall rates of death from 
cardiovascular causes were similar for the rofecoxib and naproxen 
arms [28]. 
Jüni et al. undertook a meta-analysis of RCTs of rofecoxib, and 
they conclude that Merck’s use of composite cardiovascular endpoints 
in reports concerning rofecoxib “will have diluted any increase in risk 
of myocardial infarctions” [29]. Psaty and Furberg argue that use of 
composite endpoints “will tend to drive the relative risk toward the null 
and enhance the chances of finding a non-inferiority” status for a new 
drug undergoing clinical trial [30].
Effects on patient safety of use of surrogate endpoints in RCTs
Another potential safety risk is the acceptability of the use of 
surrogate endpoints in RCTs as substitute markers for clinical 
endpoints. These were introduced to offset the problem that testing the 
capacity of a new drug to prevent or modify an undesired long-term 
adverse clinical outcome could take a long time, because the adverse 
clinical outcome itself may take a long time to develop. It is considered 
not feasible to expect patients in active treatment groups to continue 
for the requisite time for the possibility of long-term effects becoming 
established, and it is judged improper to expect placebo groups to 
remain effectively untreated for an extended period. In other situations, 
for example, HIV research, it is considered essential to expedite the 
possibility of finding a means of treating a potentially serious morbidity 
state. 
However, use of surrogate endpoints can have an adverse effect on 
patient safety, as the surrogate endpoint becomes the focus of research. 
The effect on patient safety through the use of a surrogate endpoint is 
illustrated in the clinical trials of rosiglitazone. The long-term clinical 
endpoint was the reduction of CVD in patients with Type II diabetes. 
More than 65% of deaths in patients with Type II diabetes are from 
cardiovascular causes, and one of the principal contributors to the 
onset of CVD in these patients is the prevalence of persistent high 
blood sugar levels. Reduction of blood sugar levels was thus regarded 
as an acceptable surrogate for the capacity of the new drug to reduce 
CVD, and this endpoint was to be measured by reduction in glycated 
haemoglobin levels [31]. 
However the initial RCTs of rosiglitazone were not adequately 
powered to determine the effects of rosiglitazone on the microvascular 
and macrovascular complications of diabetes, including the clinical 
endpoint of CVD. It was not until the numbers of MIs increased in 
patients taking rosiglitazone that evidence was slowly accumulated that 
the drug itself directly caused MIs. The time lapse in establishing that 
this was the case was protracted. The FDA Office of Surveillance and 
Epidemiology has calculated that there were between 41,000 to 205,000 
major cardiovascular events in Type II diabetics which were potentially 
attributable to rosiglitazone therapy between its approval in 1999 and 
2006 [32].
Effects on patient safety of the dosage levels used in RCTs
Another issue which can skew the evidence in RCTs of new drugs 
is the use of supratherapeutic dosing of highly selected clinical trial 
populations in short-haul clinical trials. Short-term administration 
of a dose known to be considerably in excess of that necessary to 
provide symptomatic relief is sometimes used as a surrogate means of 
estimating the boundaries of safety, tolerability and efficacy of a new 
drug, as well as the risk of the new drug over time. 
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Dosage guidance that is informed by the new drug manufacturer’s 
exercise to replicate real-world tolerability, efficacy, and short- and 
long-term safety does not reliably translate into appropriate dosage 
guidance for an unscreened real-world clinical population. Adverse 
events related to drug tolerability, efficacy and patient safety will often 
show up when the drug is released into the community where patients 
with compromised health status are prescribed the new drug. 
The frequent use of contraindicated dosage levels of comparator 
drugs also makes it difficult to estimate the comparative safety of a new 
drug. The strategy of under-dosing or overdosing of comparator drugs 
is implemented in clinical trials of a new drug in order to demonstrate 
its superiority in comparison with the comparator drugs. Dosage 
levels of comparator drugs were a significant issue in clinical trials of 
rofecoxib. 
Rofecoxib was compared with a range of other drugs in various 
clinical trials, but these comparator drugs were often administered 
at levels not recommended by the manufacturers, as recorded in the 
relevant Product Information (PI). Sometimes the comparator drug 
dose was administered at a level that was higher than the manufacturer’s 
recommended dose, and sometimes it was administered at a lower level. 
The apparent intent in adopting this strategy was that the performance 
of rofecoxib would be better in terms of the relevant symptom to be 
assessed, and better in terms of fewer unwanted side-effects. 
Effects on patient safety of the pooling of RCTs
Pooling data from a number of clinical trials and presenting them as 
if they were a planned multi-site single RCT is also a way of presenting 
evidence that can make it difficult to estimate the comparative safety of 
a new drug. A study by Langman et al. [33] was presented as a “planned 
combined analysis” of eight trials, when these eight trials had different 
endpoints, were of different durations, used different dosage levels 
of the trialled drug in different trials, used different comparators in 
different trials, and different dosage levels of the those comparators in 
different trials. Statistical analyses using pooled data from a range of 
clinical trials have the potential to mask the possibility of  identifying 
patient safety signals. 
Effects on patient safety of selectivity in statistical techniques 
used in RCTs
Other important concerns with the clinical status of evidence from 
RCTs are related to the emphasis on numerical measurability, and the 
use of the EBM-preferred statistical model in the design and analysis 
of RCTs. 
Feinstein [8] observes that there are actually two aspects of 
statistical significance: quantitative significance and stochastic 
significance. Quantitative significance refers to the magnitude of an 
observed distinction within clinical trial results, and relates to the 
clinical importance of the observed difference; stochastic significance 
is a mathematical calculation that denotes the probability that an 
observed distinction within trial results might arise by chance alone. 
The p<0.05 stochastic boundary is the accepted indicator of the 
significance of an outcome from a clinical trial; however when assessing 
this statistically derived measure of significance, it is important to 
remember that, in essence, statistical significance is not a measure of 
clinical significance [8].
There is no standard for comparing quantitative (clinical) 
significance, because the importance of a quantitative clinical 
difference will vary, depending on what is the subject of the clinical 
trial. In some trials, small quantitative differences can have significant 
clinical importance; in other trials, even large quantitative differences 
may not have significant clinical importance. For example, the accepted 
measure of statistical significance (p<0.05) suggests that a result is 
significant if it has only a 1 in 20 likelihood of being due to chance. 
However the clinical significance of that finding is far greater if that 
chance translates as death or serious morbidity, compared with, say, a 
side-effect such as nausea.                                                                                 
Cochrane [34] also comments that it is often possible to achieve 
a result that is statistically significant but which may be clinically 
unimportant, and he notes that these estimates of significance are very 
dependent on the numbers enrolled in the clinical trials. Feinstein [8] 
notes that “for the stochastic aspects of significance, nothing will be 
significant if the group size is too small, and anything can be significant 
if the group is big enough”. The presence of the p<0.05 boundary for 
significance is a statistical artefact. 
Using stochastic probability techniques to calculate the significance 
of RCT results allows mathematical constructs to decide what is or is 
not clinically important, and what may be clinically unsafe may be 
masked in the numbers. 
Kerridge et al. note the patient safety issues relating to within-trial 
averaging, and they argue that “the overall results of a trial represent an 
average effect, and even within a trial population, some will experience 
a greater than average improvement in outcomes, while others may 
suffer harm” [35]. Kotaska confirms this in his observation that the 
mean outcome for all participants means that clinically important 
safety factors relating to individuals can be lost [25].
Overall, then, the range of controls and protocols that can be used 
in the design, conduct, and analysis of RCTs do not necessarily render 
the evidence derived via an RCT as ‘above reproach’ in relation to 
patient safety. 
Who is responsible for identifying patient safety issues 
associated with new drugs?
The process of analysing patient safety issues in the RCTs submitted 
in support of an application for approval of a new drug is the statutory 
responsibility of national drug regulatory authorities. These same 
authorities are responsible for setting up systems to record details of 
post-marketing adverse drug events. 
However assessing pre-approval and post-marketing drug safety is 
costly and time-consuming, and both of these processes can be subject 
to political pressures.
Effects on patient safety of funding agreements between 
manufacturers and drug regulatory  authorities
Funding agreements for regulatory agencies have been 
implemented by various national regulatory authorities as a means of 
cost containment (e.g. the U.S. Prescription Drug User Fee Act, or the 
Australian Therapeutic Goods Amendment Act). These agreements 
require manufacturers of new drugs to pay the ‘independent’ national 
regulatory agency for the new drug approvals process, and, as a quid 
pro quo, these agreements allow manufacturers to set statutorily agreed 
performance requirements relating to the time taken to complete the 
approvals process. 
Effects on patient safety of the U.S. prescription drug user fee 
Act 
To illustrate the influence of the joint government and manufacturer 
Page 5 of 8
Citation: Whitstock MT,  Pearce CM, Eckermann EJ (2011) Randomised Controlled Trials and ‘Unexpected’ Adverse Events Associated with Newly 
Released Drugs: Improvements in Pharmacovigilance Systems are Necessary for Real-Time Identification of Patient Safety Risks. J Clinic 
Toxicol S2:001. doi:10.4172/2161-0495.S2-001
J Clinic Toxicol        Adverse Drug Reactions and Toxico Surveillance           ISSN: 2161-0495 JCT, an open access journal
agreements, the current version of the U.S. Prescription Drug User Fee 
Act (PDUFA) requires that the FDA is to complete the assessment 
process for 90% of applications for new Priority Drugs in 6 months, 
and 90% of applications for new Standard Drugs are to be completed in 
10 months [36]. It is the manufacturer who makes the case that a new 
drug is an advance over currently available therapy, which then places 
that drug in the Priority Drug group. 
The FDA new drug approval process is now amongst the shortest in 
the world, and the average time it takes for the FDA to approve a new 
drug has dropped by 40% since the first implementation of PDUFA in 
1992. This has contributed to raising the U.S. share of the world’s new 
drug launches from 8% to 50% [9]. From the patient safety perspective, 
this could be considered as representing an increased worldwide 
exposure to drug safety issues generated within the U.S. regulatory 
framework.
Carpenter et al. [37] have explored the impact of accelerated 
PDUFA deadlines on the quality of decision-making in drug safety 
assessments, and they find that pre-deadline approvals are associated 
with three to five times the rate of safety-based withdrawal from the 
global market for all classes of drugs. The shortened times of the FDA 
new drug approvals process involves approvals being made early 
in the clinical development process, reducing the time-window for 
recognising adverse drug events [38]. 
For example, Dr M. Villalba, in her Medical Officer Review of the 
New Drug Application NDA 21-042 (rofecoxib), expressed concern 
in her official summary about a group of six-week trials that were 
submitted by the manufacturer as part of the supporting data in 
the application for approval to market rofecoxib. She noted that the 
data in these six-week trials suggested that thromboembolic events 
were more frequent in patients receiving rofecoxib than placebo 
[39]. Villalba noted that “with the available data, it is impossible to 
answer with complete certainty whether the risk of cardiovascular 
and thromboembolic events is increased in patients on rofecoxib” 
and she recommended larger studies to answer this and other safety 
comparisons” [39]. 
Rofecoxib had been nominated by the manufacturer as a 
Priority Drug, and the review process was required to be completed 
in six months. The drug was approved in this time-frame, and it 
went on to be the cause of many thousands of cases of cardio- and 
cerebrovascular morbidity and mortality until it was withdrawn. 
Rofecoxib was approved when not enough was known about 
its action in precipitating adverse thromboembolic processes. 
The antibiotic drug telithromycin is another example of a drug with 
an expedited release onto the market in 2004 without appropriate 
safety testing. Even in the short term, it caused significant morbidity 
and mortality before it was withdrawn. Users consistently experienced 
symptoms ranging from impaired vision to liver toxicity, yet these 
symptoms were not explored fully in the pre-release stage [40]. 
Ironically, the PDUFA arrangements were initiated partly as a 
result of consumer dissatisfaction with the time taken to get new drugs 
(especially those for HIV) on the market. Yet by 2007, even before the 
rofecoxib case had come to a head, there was concern that the FDA 
regulatory body was becoming accountable to the pharmaceutical 
industry it regulated [38]. Now it appears to be the case that new 
drugs are being approved in too short a time-frame, and before the 
2007 renewal of the PDUFA agreement, there were many concerned 
scientists and FDA staff who lobbied to have the FDA funded by 
government appropriation, with no controlling involvement by 
industry.
 In interviews conducted in 2003 by the U.S. Department of Health 
and Human Services, 58% of FDA staff reported that the 6-month 
Priority Drug approval time-frame does not allow for in-depth, 
science-based reviews, and that this was contributing to the likelihood 
of adverse drug events remaining unrecognised until after the new drug 
is approved [41]. This effectively shifts issues relating to adverse drug 
events to national adverse event reporting systems.
Effects on patient safety of relying on adverse event databases
Relying on checking adverse event reporting databases to provide 
information on risks to patient safety is problematic. Reports to such 
databases are inherently subject to Type I and Type II errors, as there is 
no accurate information on the actual number of events in the exposed 
population or the actual number of exposed individuals [42]. Adverse 
event reports are also subject to major under-reporting. In 2004, 
Trontell, of the FDA Office of Surveillance and Epidemiology, reported 
that the U.S. FDA MedWatch / AERS (Adverse Event Reporting 
System) may receive as little as 1% of all adverse events which occur in 
the population [43]. 
Troy, former chief counsel at the FDA, commented in 2007 that 
“the FDA generally assumes that only 1 in 10 adverse events is reported 
[44]”. Other drug regulatory jurisdictions suffer from the same 
problems. In practice, reported ADEs are regarded as being outliers 
until the rate and the number of reported adverse events force another 
look at the way in which the relevant RCT was designed. 
In regulatory jurisdictions where reporting of potential adverse 
drug events is voluntary, even if there are electronic options 
available for reporting, this ‘outlier’ issue will apply. The value 
of the mandatory aspect of the process vs. the voluntary aspect 
is shown in the managed manual reporting regime in the U.K. 
As part of the U.K. Prescription-Event Monitoring (PEM) system [45], 
managed by the independent Drug Safety Research Unit (DSRU), all 
U.K. GPs are required to complete a form reporting on a broad range 
of medical events that have been recorded in a patient’s notes during 
a specific time-period since the patient started treatment with a new 
drug. This manual reporting process is undertaken for the first 10,000 
users of a new drug. Removing the need for the prescribing doctor to 
give an opinion about whether an event might have been caused by the 
new drug provides the opportunity to identify adverse events that may 
not have been suspected as being due to the drug that is under post-
marketing surveillance. 
Reporting in this manner neutralises the problems with Type I and 
Type II errors which occur in the FDA AERS. Data components are 
individually examined, and large cohorts are processed electronically. 
The DSRU states that the Prescription-Event Monitoring is the only 
method of post-marketing surveillance in Europe that can evaluate the 
safety of new medicines soon after launch [45].
Effects on patient safety of manufacturers’ responses to risks 
identified after the approval of a new drug
Should a national regulatory authority consider that the 
accumulation of adverse event reports indicates patient safety 
concerns, the manufacturer can be required to make changes to the 
product labelling. However, the wording to be used, and the placement 
of the labelling changes, remain the prerogative of the manufacturer. 
The process is one not welcomed by manufacturers, as they consider 
that such changes will affect sales, and there have been egregious cases 
where procrastination has meant that details of risks to patient safety 
were not communicated to prescribers and patients for extended 
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periods [46-47]. In one case, two manufacturers refused to comply with 
a labelling change required by a national regulator: one manufacturer 
took the issue to the Federal Court; the other petitioned the relevant 
Federal Minister [48]. 
In the U.S., the Food and Drug Administration Amendments Act 
2007 (FDAAA 2007) places an upper limit of 80 days on the process 
of settling safety labelling issues required after post-marketing studies 
[49]. Assuming that this process is complied with, there is at least some 
expectation that U.S. patients and their physicians will be made aware 
of safety issues in a more helpful time-frame.
Overall, the current post-approval identification of, and action on, 
patient safety signals associated with new drugs do not well serve the 
consumers of these drugs, and it is essential that processes that allow 
closer to real-time assessment of ADEs can be developed.
Before focusing on these processes, we include a brief discussion 
on a side issue on the proposed responsibility of practitioners to assess 
reports of RCT evidence. 
Should practitioners assess new drug RCTs themselves?
EBM praxis proposed initially that practitioners themselves should 
locate evidence from published RCTs of treatments that were possibly 
applicable to their patients, and then assess these RCTs for compliance 
with an ideal RCT study design and for suitability for their patients. 
The process was represented as “a simple, logical process for reasoning 
and decision making” [35]. But time proved critical on many fronts 
[50], and the emphasis shifted to group development of clinical practice 
guidelines based on RCTs. The outcome is multiple clinical guidelines 
with multiple requirements that are not necessarily compatible. 
Many RCTs are published multiple times in different journals 
using different orders of author names, and different titles for the 
trials. It is possible for practitioner assessors of new drugs to think that 
certain positive results are supported by many RCTs when in fact they 
are duplicates. The true levels of ADEs are masked. In an editorial on 
the fair conduct and fair reporting of clinical trials, Rennie argues that 
covert reporting of the same data in clinical trials artificially skews the 
balance of opinion in favour of a new drug, giving an impression of 
wide support for the efficacy of an intervention [51].
Meta-analyses of RCTs are also proposed as an aid to practitioners 
to assess the evidence from RCTs. The meta-analysis process applies 
specific statistical operations to harness the potentially greater power 
of larger numbers through combining studies to arrive at an overall 
assessment of the effectiveness of a particular intervention. However, 
small or poorly conducted clinical trials produce different effect 
estimates than those trials that are methodologically rigorous. The 
importance of this exaggeration of benefits factor is that when data 
from these trials are included in meta-analyses, they contribute to a 
skewed result [52]. 
An examination of 11 randomly selected meta-analyses of 127 
RCTs, involving over 10,000 patients, showed that when the results 
of low- and high-quality RCTs were pooled in the relevant meta-
analyses, there was a significant 30-50% exaggeration of the efficacy 
of the trialled interventions across the 11 meta-analyses as a result of 
the inclusion of the low-quality RCTs [53]. The value to clinicians of 
evidence from meta-analyses is only as useful as the methodology that 
underpins each RCT. 
Surveillance methods which attempt to give closer to real-
time identification of patient safety signals for newly released 
drugs 
RCTs are primarily about assessing how a new drug works for the 
population in the clinical trials, and not about which patients in the 
wider community can benefit, and even in the case of well-conducted 
clinical trials, it is expected that there will be unaddressed patient safety 
risks for members of the wider population for whom the new drug is 
prescribed. 
Adverse event monitoring systems relying on the reporting of 
ADEs that occur in the wider population exposed to a new drug will 
suffer from a time-lag until there are sufficient data that indicate there 
is a growing problem. This time-lag will be greater when the reporting 
of ADEs is voluntary, as noted earlier. 
The search for improved identification of ADEs has focused on 
what systems can be put in place that can prospectively identify risk. 
The key to closing the gap between the release of a drug, and the 
identification of ADEs associated with its use is access to data that can 
link patients with medications and with diagnoses. This requires the 
development of very large linked systems, and of techniques that will 
support the analysis of the data available. 
Examples of the capacity of large integrated systems to detect 
early safety signals associated with new drugs are seen in the EU-ADR 
Project [54], the HMORN (CERT) Project [55-56] and the Sentinel 
System [57], each discussed below. The aim of these projects is to exploit 
information from electronic healthcare record databases to develop an 
integrated system for the early detection of drug safety signals. 
Also discussed is an Australian initiative designed to offset some 
of the patient safety issues associated with the use of RCT controls. 
The model system works by prospectively identifying patient groups 
potentially at risk of an ADE if prescribed a newly released drug. The 
system uses linked de-identified national medications dispensing and 
hospital separations diagnoses data to establish the morbidity profiles 
of patients who have the morbidity (or morbidities) that are the target 
of a new drug. These are then compared with the patient profiles of the 
participants selected to participate in the clinical trials of that new drug 
in order to assess safety risk.
The EU-ADR Project
The EU-ADR (Exploring and Understanding Adverse Drug 
Reactions) is a proof-of-concept project drawing on retrospective 
anonymised aggregated demographic, outpatient, inpatient, and 
medication prescription data from eight databases in four European 
countries (Denmark, Italy, the Netherlands and the U.K.). All eight 
systems are record-linkage systems in which drug dispensing data 
are linked to a registry of hospital separations diagnoses (as well as 
other registries). Data were pooled via a distributed network approach 
by generation of common input data, followed by local aggregation 
through custom-built software (Jerboa®). The distributed study 
population was 19.6 million individuals, which corresponded to 60 
million person-years of follow-up. 
The retrospective proof-of-concept exercise using EU-ADR linked 
data showed a consistent association of a specified drug class (NSAIDs) 
with an increased risk of a specified morbidity (upper gastrointestinal 
bleeding) in all eight databases. When the system is used in the future 
for real-time early detection of drug safety signals, it is proposed that 
the safety signals will be substantiated by semantic mining of the 
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relevant literature, and computational analysis of pharmacological and 
biological information on drugs, molecular targets, and pathways. 
The (HMORN) (CERT) Project
The objectives of the U.S. Health Maintenance Organization 
Research Network (HMORN) Center for Education and Research 
(CERT) project were to evaluate the utility of automated healthcare 
claims data for near-real-time adverse event surveillance, and to 
identify methodological issues related to this. Nine participating health 
plans provided data for over 8 million members, with 13 million 
person-years of follow-up over a 6-year period.
The project assessed the ability to detect ADEs using retrospective 
data from nine health plans, using a maximised sequential probability 
ratio test (maxSPRT). The maximised sequential probability ratio test 
was used because to realise the full potential of prospective adverse 
event surveillance, accumulated drug exposure and adverse event 
experience should be evaluated as they accumulate in a way that avoids 
problems associated with repeated statistical tests on the same data. 
The intent of sequential analysis is to quickly and efficiently detect 
signals of excess risk using data that are routinely collected by most 
public and private health insurers in the U.S., and the highly summarised 
data used in the analysis process preserves patient confidentiality. The 
investigators noted that positive safety signal detection does not imply 
a causal relationship, and all signals need to be evaluated for clinical 
importance. 
The U.S. Sentinel System 
The FDA announced the Sentinel System initiative in May 2008 
[51]. This private-public system will eventually be able to search the 
electronic health data of a minimum of 100 million patients to determine 
the existence and/or severity of risk factors. Users of the Sentinel 
System will include government and private sector organisations and 
academia. The current infrastructure is supported by the FDA, but it 
is anticipated that Sentinel will be a distributed system (as is used in 
the EU-ADR project) managed by a consortium of interested parties 
operating as a public–private partnership.
Mini-Sentinel, the pilot program currently underway, has initially 
focused on developing the ability of participating health plans and 
other private organisations to create data files in a standard format and 
to maintain control of those files. These private organisations perform 
most analyses of their own data by running computer programs 
distributed by a coordinating centre, and they provide consistent 
summarised results for review by the FDA.
It is anticipated that the FDA will soon begin to actively monitor 
the data, seeking answers to specific questions about the performance 
of medical products [51]. 
Using clinical trial and linked administrative health data to 
prospectively identify potential patient safety risk
Whitstock et al. [12] trialled a model process that used clinical trial 
data and linked administrative health data to support a prospective 
assessment of patient groups who could potentially be at risk of an 
adverse drug event if they are prescribed a newly released drug in the 
context of their age, gender, comorbidities and/or co-medications.
Using clinical trial data required under U.S. law to be made publicly 
available, it is possible to develop a profile of the participants in the 
RCTs of a new drug. Information includes details on study designs, 
primary and secondary outcome measures, participating patient 
demographics, eligibility criteria (including exclusion protocols), 
withdrawals and exclusions from the final analysis, tables of values for 
primary and secondary outcome measures, and statistical analyses.
Using linked Australian de-identified administrative health data 
on patient hospital separation diagnoses and patient medications 
dispensed, it is possible to develop a morbidity profile of the patients 
who suffer from the morbidity (or morbidities) targeted by that new 
drug. The clinical trial information and the linked morbidity and 
medication data are compared to assess which patient groups could 
potentially be at risk of an adverse drug event associated with use of 
the new drug. 
An advisory can be circulated to physicians to recommend care 
prescribing of that drug to patients with comorbidities or taking co-
medications that have been excluded in the RCTs of that new drug, at 
least until more is known. 
As the majority of new drugs are likely to be prescribed to older 
patients who have one or more comorbidities in addition to that 
targeted by a new drug, and as the RCTs of those drugs typically under-
represent the elderly and exclude patients with multiple comorbidities 
[5, 15-16], undertaking an exercise such as this could reduce the 
numbers of ADE in patients who have health profiles that would have 
excluded them from the RCTs of a new drug.
Conclusion
The RCT study design may be the prioritised source of best 
evidence, but the procedural controls that can be exercised within 
that study design mean that applying this evidence can pose risks to 
patient safety. Identification of these risks must be made as soon as 
possible. Currently available adverse event reporting systems do not 
have the capacity to support that needed timely identification. Real-
time or prospective identification of patient safety risks is essential in 
an environment where more and more new drugs are being launched.
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